Biomerica, Inc. announced that findings from a clinical trial for its inFoods IBS blood test have been published in *Gastroenterology*, demonstrating significant relief from abdominal pain for Irritable Bowel Syndrome (IBS) patients. The study showed that participants who adhered to a personalized diet therapy based on the test results experienced greater symptom improvement compared to those following a sham (placebo) elimination diet. The inFoods IBS test identifies individual foods that trigger elevated Immunoglobulin G (IgG) antibody responses, a marker of inflammation associated with IBS symptoms.
The randomized, multicenter, double-blind, placebo-controlled trial enrolled 238 IBS patients across eight leading academic centers in the U.S. The study found that 59.6% of patients in the treatment group met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group. Notably, the benefits were most pronounced in patients with IBS-C (constipation-predominant IBS) and IBS-M (mixed constipation and diarrhea), with 67.1% and 66% respectively meeting the FDA target for pain reduction.
The positive results observed in IBS-M patients are particularly significant, as no FDA-approved medications currently exist for treating this IBS subtype. This research takes a targeted approach using an IBS-specific IgG test to personalize dietary recommendations, offering a proactive approach to managing IBS by avoiding symptom triggers. The publication in a leading GI medical journal provides strong scientific validation for the inFoods IBS test.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.